Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
The substantial progress made in the basic sciences of the brain has yet to be adequately translated to successful clinical therapeutics to treat central nervous system (CNS) diseases. Possible explanations include the lack of quantitative and validated biomarkers, the subjective nature of many clin...
Saved in:
Main Authors: | Hugo Geerts (Author), John Wikswo (Author), Piet H. van derGraaf (Author), Jane P.F. Bai (Author), Chris Gaiteri (Author), David Bennett (Author), Susanne E. Swalley (Author), Edgar Schuck (Author), Rima Kaddurah‐Daouk (Author), Katya Tsaioun (Author), Mary Pelleymounter (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Salvaging CNS Clinical Trials Halted Due to COVID‐19
by: Hugo Geerts, et al.
Published: (2020) -
A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
by: Hugo Geerts, et al.
Published: (2023) -
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies
by: Peter Bloomingdale, et al.
Published: (2021) -
Application of quantitative systems pharmacology to guide the optimal dosing of COVID‐19 vaccines
by: Mario Giorgi, et al.
Published: (2021) -
Editorial: Drug discovery and development explained: introductory notes for the general public
by: Bruno O. Villoutreix, et al.
Published: (2024)